Skip to main content
S&P 5007,694.43-0.63%DOW51,539.27-0.56%NASDAQ26,872.86-0.72%BTC$83,628.00-1.09%ETH$2,683.03-0.36%GOLD$4,154.30-3.86%OIL$94.49+2.25%
Smart Investors Daily
SN

NYSE · SNY

Sanofi

Healthcare · Drug Manufacturers - General

$41.11

Down-$0.08 (-0.19%)

Updated Sep 28, 2026, 3:56 PM

SID Score

6.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
119.04B
P/E ratio
11.2
Dividend yield
5.38%
52-week range
$40.66 – $52.68
Volume
2.22M
Avg. volume
2.95M

Price performance · SNY

SNY price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Sep 25, 2026

SNY closed at $41.11 after 19 trading sessions, down 7.33% for the selected period.

Last close
$41.11
Period change
-7.33%
Period low
$40.94
Period high
$44.47
Daily close
View OHLC price history
SNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 25, 2026$40.89$41.12$40.655$41.112.22M
Sep 24, 2026$41.225$41.605$40.905$40.943.07M
Sep 23, 2026$41.85$41.96$41.405$41.663.84M
Sep 22, 2026$42.34$42.62$42.03$42.513.08M
Sep 21, 2026$42.64$42.775$42.47$42.502.48M
Sep 18, 2026$42.75$42.77$42.34$42.482.24M
Sep 17, 2026$42.82$43.23$42.82$43.142.96M
Sep 16, 2026$42.72$43.00$42.52$42.592.43M
Sep 15, 2026$42.78$42.89$42.38$42.402.68M
Sep 14, 2026$43.70$43.74$43.015$43.332.33M
Sep 11, 2026$42.81$42.885$42.41$42.772.37M
Sep 10, 2026$42.86$43.05$42.67$42.721.96M
Sep 9, 2026$43.08$43.46$42.8205$42.851.95M
Sep 8, 2026$43.49$43.71$43.14$43.1552.6M
Sep 4, 2026$44.17$44.36$44.025$44.241.7M
Sep 3, 2026$45.15$45.16$44.20$44.332.4M
Sep 2, 2026$44.68$45.22$44.43$44.472.17M
Sep 1, 2026$45.08$45.23$44.205$44.372.02M
Aug 31, 2026$44.59$44.69$44.26$44.362.35M

Latest SNY news

The latest Smart Investors Daily articles mentioning SNY.

Stock researchCompany · Overview

SNY research

Overview

Company profile and research snapshot.

Company profile

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$57.02
Implied upside
—
Analysts
14
SNY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNNeutral—
Sep 21, 2026BERENBERGBuy—
Sep 8, 2026LEERINK PARTNERSOutperform—
Sep 4, 2026ODDO BHFBuy—
Aug 31, 2026INTESA SANPAOLO EQUITY RESEARCHBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

Yahoo · Sep 22, 2026

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By